SecBot SecBot
8-K ·Filed Nov 4, 2026

MYGN

MYRIAD GENETICS INC
MIXED
Impact 6/10
Horizonmonths Processed12d 8h ago SEC0001628280-26-070135
8-K Item 2.02: Earnings release
Actionable Insight ◆ Mixed

The Prenatal Health sale simplifies the business and provides $210M cash to strengthen the balance sheet, but the core Cancer Care Continuum and Mental Health revenue grew only 1% combined YoY. Monitor the close of the Labcorp transaction and any updates on Medicare coverage for Precise MRD, which could be a catalyst for 2027 growth.

DirectionMixed
Confidencehigh
Horizonmonths

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+5
Entry
$6.29
T+0 close · Nov 4, 2026 · via day close
Latest settled
−9.70%
T+5 · $5.68 · next T+20 in 17d
Vs SPY
−12.99%
α at T+5
Latest observation
−10.39%
T+6 · FF3 residual α
  1. T+0 · Nov 5 $6.29entry
  2. T+1 · 11d ago −5.88%α −6.19% · $5.92
  3. T+5 · 5d ago −9.70%α −12.99% · $5.68
  4. T+7 · todayOpen
  5. T+20 · in 17d Pending
  6. T+60 · in 3mo Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Myriad Genetics reported Q3 2026 revenue of $202.7M, above the $191.3M consensus, but GAAP net loss widened to $43.9M ($0.46 per share) from $27.4M a year ago. The company raised the mid-point of its full-year 2026 revenue guidance to $780M-$790M and announced a definitive agreement to sell its Prenatal Health business to Labcorp for $210M in cash, expected to close by early 2027.

Key Financial Metrics

EPS (Adj.)
−$0.11
GAAP: $-0.46
Revenue
$202.7M
est $191.3M · +6.0% · -1.5% YoY
Guidance
$780M-$790M
raised
Free Cash Flow
$1.6M
Gross Margin
67.9%

Key Facts

  • Q3 2026 revenue $202.7M, up 6% sequentially but down 1% YoY, above the $191.3M consensus
  • GAAP net loss $43.9M ($0.46 per share) vs $27.4M loss a year ago; adjusted loss per share $0.11
  • Full-year 2026 revenue guidance raised to $780M-$790M (mid-point raised from $870M prior range, reflecting the Prenatal divestiture)
  • Definitive agreement to sell Prenatal Health business to Labcorp for $210M cash plus inventory value, expected to close by early 2027
  • Cancer Care Continuum revenue $123.9M, up 1% YoY; Mental Health revenue $39.5M, up 2% YoY; Prenatal Health revenue $39.3M, down 12% YoY
  • Cash and cash equivalents $107.1M at quarter end; adjusted free cash flow positive $1.6M in Q3

Financial Impact

Revenue beat consensus by $11.4M (6.0%); Prenatal sale valued at $210M cash, roughly 38% of market cap

revenuenet lossguidancecash flow

Segment Breakdown

SegmentRevenueGrowth
Cancer Care Continuum$123.9M+1.1%
Mental Health$39.5M+2.1%
Prenatal Health$39.3M-11.7%

Risk Factors

  • Prenatal Health sale may not close on expected timeline or at all, subject to regulatory approvals
  • Core revenue growth remains low single-digit; GAAP losses continue to widen
  • Adjusted gross margin declined 200 bps YoY to 67.9%, reflecting lower volumes and investment costs

Market Snapshot

Exchange
Nasdaq
Sector
In Vitro & In Vivo Diagnostic Substances
Analyst Consensus
7% bullish (14 analysts)

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001628280-26-070135
Document: mygn-20261104.htm0001628280-26-070135
Document: 0001628280-26-070135-index-headers.html0001628280-26-070135
Document: 0001628280-26-070135-index.html0001628280-26-070135
Document: 0001628280-26-070135.txt0001628280-26-070135
8-K Data (Synthetic)0001628280-26-070135

Track record

16 reports on MYGN

Performance horizon

3 of 4 bullish or bearish reports moved the stock their way by T+1. Best: +13.54% at T+5 after the Oct 20, 2026 report. 3 of 4 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G/A Bearish 4/10 Entry $5.57 Now $5.57 −0.00% settles Nov 18
  2. Nov 9, 20267d ago 8-K Neutral 2/10 Entry $5.67 to $5.72 Now $5.57 −1.76% ▲ +0.88% −0.44% vs SPY
  3. Nov 5, 202611d ago 8-K Neutral 4/10 Entry $6.29 to $5.92 Now $5.57 −11.45% ▼ −5.88% −6.19% vs SPY
  4. Nov 4, 202612d ago 8-K Mixed 6/10 Viewing Entry $6.29 to $5.92 Now $5.57 −11.45% ▼ −5.88% −6.19% vs SPY
  5. Nov 4, 202612d ago Institutional Cluster Neutral 2/10 Entry $6.02 to $6.29 Now $5.57 −7.48% ▲ +4.49% +8.89% vs SPY
  6. Oct 27, 202620d ago SC 13G/A Neutral 2/10 Entry $6.63 to $6.67 Now $5.57 −15.99% ▲ +0.60% +0.99% vs SPY
  7. Oct 20, 202627d ago 8-K Bullish 7/10 Entry $5.54 to $5.57 Now $5.57 +0.54% ▲ +0.54% +0.02% vs SPY
  8. Oct 15, 20264w ago Press Release Neutral 1/10 Entry $3.98 Now $5.57 +39.95% No price data
  9. Oct 9, 20265w ago 8-K Neutral 3/10 Entry $4.20 to $4.08 Now $5.57 +32.62% ▼ −2.86% −2.85% vs SPY
  10. Sep 16, 20268w ago 8-K Neutral 3/10 Entry $3.86 to $4.14 Now $5.57 +44.30% ▲ +7.25% +6.12% vs SPY
Showing 10 of 16

US Market Status

Market Closed · Opens in 9h 8m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 4, 2026